- Home
- NEUP vs BRTX Comparison
NEUP vs BRTX Comparison
Compare NEUP & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEUP
- BRTX
- Stock Information
- Founded
- NEUP 1996
- BRTX 1997
- Country
- NEUP United States
- BRTX United States
- Employees
- NEUP N/A
- BRTX N/A
- Industry
- NEUP
- BRTX Managed Health Care
- Sector
- NEUP
- BRTX Health Care
- Exchange
- NEUP Nasdaq
- BRTX Nasdaq
- Market Cap
- NEUP 12.7M
- BRTX 12.5M
- IPO Year
- NEUP N/A
- BRTX N/A
- Fundamental
- Price
- NEUP $9.40
- BRTX $1.45
- Analyst Decision
- NEUP Strong Buy
- BRTX
- Analyst Count
- NEUP 2
- BRTX 0
- Target Price
- NEUP $28.00
- BRTX N/A
- AVG Volume (30 Days)
- NEUP 86.8K
- BRTX 102.9K
- Earning Date
- NEUP 11-15-2025
- BRTX 11-11-2025
- Dividend Yield
- NEUP N/A
- BRTX N/A
- EPS Growth
- NEUP N/A
- BRTX N/A
- EPS
- NEUP 0.00
- BRTX N/A
- Revenue
- NEUP $15,662,715.00
- BRTX $605,200.00
- Revenue This Year
- NEUP N/A
- BRTX $232.67
- Revenue Next Year
- NEUP N/A
- BRTX $52.92
- P/E Ratio
- NEUP $5,650.38
- BRTX N/A
- Revenue Growth
- NEUP N/A
- BRTX 247.62
- 52 Week Low
- NEUP $2.90
- BRTX $1.21
- 52 Week High
- NEUP $126.00
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- NEUP 43.51
- BRTX 39.76
- Support Level
- NEUP $11.42
- BRTX $1.42
- Resistance Level
- NEUP $15.14
- BRTX $1.63
- Average True Range (ATR)
- NEUP 1.62
- BRTX 0.08
- MACD
- NEUP -0.38
- BRTX -0.02
- Stochastic Oscillator
- NEUP 2.05
- BRTX 6.38
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.